Inclusion Criteria:

          -  Patients diagnosed with epithelial ovarian cancer, fallopian tube cancer, or
             peritoneal cancer based on histologic findings obtained from biopsy/surgery and having
             a histologic type of high-grade serous cancer.

          -  In the absence of a mutation of the BRCA gene (no germline mutation should be
             identified, not in the case of a somatic mutation)

          -  Recurrence within 6 months after platinum-based chemotherapy.

          -  ECOG performance 2 points or less.

          -  Blood tests performed within 2 weeks of enrollment meet the following results:
             Neutrophil > 1,500/mm3; Platelet > 100,000/mm3; Hemoglobin > 9.0 g/dL; Total bilirubin
             < 1.5 x upper limit of normal (ULN); AST/ALT < 3.0 x ULN (or < 5 x ULM in case of
             liver metastases); Creatinine < 1.5 x ULN; Electrolytes should be within normal
             limits.

          -  Patients who understand the content of the study description and voluntarily agree in
             writing.

          -  Patients who are willing and able to adhere to the visit schedule, treatment plan,
             laboratory tests, and other testing procedures.

        Exclusion Criteria:

          -  Patients previously treated with three or more anticancer regimens. Maintenance
             therapy is not considered a separate regimen (eg> paclitaxel-carboplatin-bevacizumab
             therapy). In the combined chemotherapy, when one drug is subtracted due to toxicity,
             the regimen is not counted as a change (Eg> paclitaxel-carboplatin chemotherapy,
             paclitaxel was discontinued due to neurotoxicity and carboplatin alone was not
             considered as a change of regimen).

          -  Previous refractory to ovarian cancer chemotherapy.

          -  Patients diagnosed with other tumors other than ovarian cancer for the last 5 years
             (not CIS).

          -  pregnant woman.

          -  Patients with uncontrolled infection.

          -  In the case of congenital immune disease or acquired immune deficiency syndrome.

          -  Women in lactation.

          -  History with Grade 3 or higher peripheral neuropathy.

          -  History of hypersensitivity reactions to PLD or bortezomib.

          -  If the physician is judged to have any serious illness or medical condition for which
             the patient is not suitable for the study.

          -  Patients with confirmed BRCA somatic mutations.

          -  Patients with acute diffuse infiltrative lung disease and cardiovascular disease.